Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment

Atherosclerosis

Volumn 57, Issue 2-3, 1985, Pages 293-301

  Gurakar, Arzu ^a   Hoeg, Jeffrey M ^a   Kostner, Gerhard ^c   Papadopoulos, Nicholas M ^b   Brewer Jr , H Bryan ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b CLINICAL CENTER   (United States)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Hypercholesterolemia; Lipoprotein Lp(a); Lipoproteins; Low density lipoproteins; Neomycin; Niacin

Indexed keywords

LIPOPROTEIN; NEOMYCIN; NICOTINIC ACID;

BLOOD AND HEMOPOIETIC SYSTEM; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG COMPARISON; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; PRIORITY JOURNAL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; NEOMYCIN; NIACIN;

EID: 0022360376     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(85)90041-3     Document Type: Article

References (31)

1. A new serum type system in man — The Lp system
2. Characterization of the Lp(a) lipoprotein in human plasma
3. Studies on the Lp(a) lipoprotein of human serum
4. Protein and carbohydrate composition of Lp(a) lipoproteins from human plasma
5. f 0–2
6. Serum lipoprotein patterns in patients with coronary atherosclerosis
7. Lp(a) lipoprotein and pre-beta lipoprotein in young adults
8. Quantitative genetic studies of the human plasma Lp(a) lipoprotein
9. An improved method for enzymatic determination of serum triglycerides
10. Lp(a) lipoprotein — Relationship to sinking pre-beta lipoprotein, hyperlipoproteinemia, and apolipoprotein B
11. Radioimmunoassay of human plasma Lp(a) lipoprotein
12. Cholesterol methodologies — A review
13. Hyperlipoproteinemia phenotype determination by agarose gel electrophoresis updated
14. Studies on the metabolism of the lipoprotein Lp(a) in man
15. Turnover of lipoprotein(a)
16. Lipoprotein Lp(a) and the risk for myocardial infarction
17. 2+ precipitation procedure for quantitation of high density lipoprotein cholesterol
18. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a)
19. Heterogeneity of lipoprotein electrophoretic patterns in patients with type II hyperlipoproteinemia
20. Human plasma lipoprotein(a)
21. Can serum Lp(a) concentration be lowered by drugs and/or diet?
22. The Lipid Research Clinics Coronary Primary Prevention Trial Results Part 1 (Reduction in incidence of coronary heart disease)
23. The Lipid Research Clinics Coronary Primary Prevention Trial Results Part 2 (The relationship of reduction in incidence of coronary heart disease to cholesterol lowering)
24. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis — Results of the NHLBI type II coronary intervention study
25. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease — Results of the NHLBI type II coronary intervention study
26. Recommendations for treatment of hyperlipidemia in adults — A joint statement of the nutrition committee and the council on arteriosclerosis
27. Lipoprotein(a) bei koronarer Herzkrankheit und Myokard-infarkt
28. Neomycin and plasma lipoprotein in type II hyperlipoproteinemia
29. Combination use of neomycin and niacin normalizes the plasma lipoprotein concentrations in type II hyperlipoproteinemia
30. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol